Detailed Narrative
Q4 & FY25 Financial Performance Highlights
Hikal reported a robust Q4 FY25 with revenue of ₹552 crores and EBITDA of ₹123 crores, marking a 71% sequential growth and 31% Y-o-Y growth in EBITDA. EBITDA margins significantly improved by 410 basis points to 22.4%. For the full year FY25, revenue stood at ₹1,860 crores, with EBITDA at ₹328 crores, translating to a 17.7% margin, an increase of 270 basis points from the previous year. The company also reported a PAT of ₹91 crores for FY25, with ROE at 7.3% and ROCE at 9.9%.
Pharma Business: Strong Growth Trajectory
The Pharmaceutical business demonstrated strong momentum, reporting Q4 FY25 revenue of ₹351 crores and EBIT of ₹55 crores. For the full year, Pharma revenue was ₹1,168 crores with EBIT of ₹137 crores, an impressive 47% Y-o-Y growth in EBIT, expanding margins by 327 basis points. Management expects the Pharma business to achieve 12-15% revenue growth in FY26, accompanied by a corresponding increase in EBIT margins, driven by an uptick in volumes, new molecules, and a healthy CDMO pipeline.
Crop Protection: Navigating Headwinds and Strategic Shift
The Crop Protection business recorded Q4 FY25 revenue of ₹201 crores with an EBIT of ₹36 crores (18% margin). For the full year, revenue was ₹692 crores and EBIT ₹79 crores (11.4% margin). This segment continues to face headwinds, particularly competitive pricing from China. Management anticipates muted or flattish growth for Crop Protection in FY26, but expects growth to resume in FY27, supported by strategic initiatives like establishing a Specialty Chemicals portfolio and advancing CDMO projects.
Animal Health Division Progress
The Animal Health Division is making steady progress, with validation of eight products completed successfully under a long-term agreement with an innovator customer. These products are slated for commercial launches across key global markets in the upcoming quarters. The company is also actively engaging with multiple new innovator customers, observing significant positive momentum and building a healthy pipeline in this high-growth segment.
Investments in R&D and New Capabilities
Hikal is committed to innovation, consistently allocating 4-5% of its revenue towards R&D. The company plans a capex of approximately ₹200 crores each for FY26 and FY27 to enhance capabilities and capacity. A new high-potency chemistry laboratory is being set up, expected to be operational by Q3 FY26, which will enable participation in more RFPs for NCEs and clinical stage materials, particularly for anticancer drugs.
CDMO Pipeline and Commercialization Outlook
The CDMO segment continues to be a key strategic driver with a healthy pipeline of development programs. Two key starting material projects for new chemical entities are progressing well in Phase III trials and are expected to transition to commercial scale in 2026-27. One of these molecules may generate revenues in FY26, with a full launch ramp-up in 2027. The company is also working on 12-15 additional new opportunities, and its food ingredient project is on track to reach peak revenue within the next 2-3 years.
Regulatory and Market Dynamics
The company acknowledged the complex global backdrop, including geopolitical uncertainty and supply chain recalibration. Regarding US tariffs, management stated the situation is complicated and they are monitoring it, but the underlying trend of outsourcing (China Plus One, Europe Plus One, US Plus One) continues to drive inquiries. Hikal has also responded to US FDA observations received in February, confirming no data integrity issues, and is awaiting the FDA's response.